Piu di un anno senza Haart con la cura della Sangamo nuovi dati
Pagina 1 di 1
Piu di un anno senza Haart con la cura della Sangamo nuovi dati
La Sangamo presenta nuovi dati a supporto della sua cura funzionale con le cosiddette "Dita di zinco" di cui si e' gia parlato piu volte. In particolare quello che colpisce e' che alcuni pazienti trattati (non viene specificao quanti n.d.r.) hanno ancora cd4 e viremia buoni dopo un anno, senza trattamento con Haart.
Sangamo Presents Functional Cure For HIV/AIDS (SGMO)
Posted: March 8, 2012 at 3:30 pm
Sangamo BioSciences, Inc. (NASDAQ: SGMO) has ticked higher on its report demonstrating that new clinical data is demonstrating persistent positive effects of ZFN Therapeutic as a functional cure of HIV/AIDS. While the term ‘Cure” is one that is up for debate, two presentations were presented this week:
“These data differentiate SB-728-T from other novel therapies as a feasible approach to controlling HIV/AIDS,” said Ronald Mitsuyasu, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA and a principal investigator in Sangamo’s SB-728-T studies. “The results suggest that SB-728-T has a positive effect on immune health of HIV-infected patients and this effect is persistent for over a year in some subjects. Most importantly, SB-728-T treatment provides HIV-resistant T-cells that are capable of mounting an immune response to an inflammatory event in lymphoid tissues and has yielded encouraging effects on HIV viral load when antiretroviral drugs are withdrawn during a treatment interruption.”
The company has a Phase II trial underway. Full details are here of the presentations this week.
[Devi essere iscritto e connesso per vedere questo link]
Sangamo Presents Functional Cure For HIV/AIDS (SGMO)
Posted: March 8, 2012 at 3:30 pm
Sangamo BioSciences, Inc. (NASDAQ: SGMO) has ticked higher on its report demonstrating that new clinical data is demonstrating persistent positive effects of ZFN Therapeutic as a functional cure of HIV/AIDS. While the term ‘Cure” is one that is up for debate, two presentations were presented this week:
“These data differentiate SB-728-T from other novel therapies as a feasible approach to controlling HIV/AIDS,” said Ronald Mitsuyasu, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA and a principal investigator in Sangamo’s SB-728-T studies. “The results suggest that SB-728-T has a positive effect on immune health of HIV-infected patients and this effect is persistent for over a year in some subjects. Most importantly, SB-728-T treatment provides HIV-resistant T-cells that are capable of mounting an immune response to an inflammatory event in lymphoid tissues and has yielded encouraging effects on HIV viral load when antiretroviral drugs are withdrawn during a treatment interruption.”
The company has a Phase II trial underway. Full details are here of the presentations this week.
[Devi essere iscritto e connesso per vedere questo link]
Gex- Admin
- Messaggi : 2565
Data d'iscrizione : 20.12.10
Argomenti simili
» Usa:56300 nuovi Hiv /anno
» Staminali della Cannon e Sangamo
» Tbc, 400 nuovi casi l'anno in Piemonte
» TBC: 8 MILIONI DI NUOVI INFETTATI OGNI ANNO
» Puglia: in un anno 32 nuovi casi diagnosticati
» Staminali della Cannon e Sangamo
» Tbc, 400 nuovi casi l'anno in Piemonte
» TBC: 8 MILIONI DI NUOVI INFETTATI OGNI ANNO
» Puglia: in un anno 32 nuovi casi diagnosticati
Pagina 1 di 1
Permessi in questa sezione del forum:
Non puoi rispondere agli argomenti in questo forum.